ProCE Banner Activity

My Take on Dolutegravir Use in Patients With Virologic Failure: Data From CROI 2022

Conference Coverage
Clinical Thought
Read my thoughts on new data from the recent CROI 2022 virtual meeting in support of using dolutegravir in second-line HIV therapy.

Released: March 14, 2022

Expiration: March 13, 2023

No longer available for credit.

Share

Faculty

Yan Zhao

Yan Zhao, MD

Professor
Division of HIV/AIDS Treatment and Care
National Center for AIDS/STD Control and Prevention
Beijing, China

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Yan Zhao, MD

Professor
Division of HIV/AIDS Treatment and Care
National Center for AIDS/STD Control and Prevention
Beijing, China

Yan Zhao, MD, has no relevant conflicts of interest to report.